Compare ACHV & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHV | NNOX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 137.8M |
| IPO Year | 2018 | 2019 |
| Metric | ACHV | NNOX |
|---|---|---|
| Price | $4.59 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.67 | $5.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $147.55 |
| Revenue Next Year | N/A | $81.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $1.59 |
| 52 Week High | $6.15 | $5.72 |
| Indicator | ACHV | NNOX |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 52.41 |
| Support Level | $4.09 | $1.63 |
| Resistance Level | $4.98 | $3.09 |
| Average True Range (ATR) | 0.40 | 0.10 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 7.56 | 90.00 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.